Osama Hallak, MD
Cardiovascular Disease · Carmel, INNPI 1154852614
Payments from drug & device makers
What this record shows
This record is dominated by grants: $26,563 of the $32,720 with a category attached, or 81.2%. Abbott accounts for 69.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $30,597 and has fallen 96.5% since, to $1,061 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $448.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$23K
- Medtronic$4K
- Boston Scientific$4K
- Edwards Lifesciences$1K
- AstraZeneca$300
- Abiomed$290
- plus $831 from 9 others
What the payments were for
- Grants$26,56381%
- Travel & lodging$2,3197%
- Food & beverage$3,17410%
- Education$5882%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $22,658 |
| Medtronic | 18 | $3,721 |
| Boston Scientific | 13 | $3,574 |
| Edwards Lifesciences | 18 | $1,345 |
| AstraZeneca | 4 | $300 |
| Abiomed | 2 | $290 |
| Chiesi USA, Inc. | 2 | $145 |
| Shockwave Medical, Inc | 1 | $129 |
| Penumbra, Inc. | 1 | $124 |
| Angiodynamics, Inc. | 2 | $123 |
| Polarityte, Inc. | 1 | $97 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $73 |
| Terumo Medical Corporation | 1 | $32 |
| Inari Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,720 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $9,016 |
| ClopidogrelClopidogrel Bisulfate | 88 | $721 |
| Atorvastatin Calcium | 41 | $254 |
| Metoprolol Succinate | 25 | $232 |
| Bumetanide | 13 | $210 |
| Rosuvastatin Calcium | 34 | $96 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 25 | $94 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Carmel
- Jerin GeorgeCarmel$76K
- Milton PresslerCarmel$25K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.